For many cancers, diagnosis is the beginning of a long journey marked by weeks of specialist appointments, imaging studies, and treatment planning. In leukemia, the timeline is often very different. One abnormal blood test can transform an ordinary day into an unexpected hospital admission, followed by a series of investigations that move much faster than most patients anticipate.
For patients and their families, this pace can be overwhelming. One day, fatigue or easy bruising may seem like the lingering effects of stress, a viral infection, or a demanding work schedule. Within days, or sometimes within hours, a hematologist may be explaining bone marrow biopsies, genetic testing, chemotherapy, and supportive care.
The speed of this process often raises more questions than answers. Why are so many blood samples needed? Why can’t treatment wait? What exactly is a bone marrow biopsy looking for? Is every leukemia treated the same way?
Understanding what happens during the first days after a leukemia diagnosis can help patients and caregivers make sense of an otherwise confusing experience. While every individual’s journey is unique, the diagnostic pathway follows well-established principles designed to identify the exact type of leukemia as quickly and accurately as possible, allowing treatment to begin without unnecessary delay.
How Does Leukemia Develop? A Brief Explanation
Leukemia begins in the bone marrow, the body’s blood-forming tissue that fills the inner cavities of many bones. All blood cells originate from hematopoietic (hemo = blood, poiesis = formation) stem cells and go through multiple stages before reaching their fully mature forms:
- Myeloid cells give rise to red blood cells, platelets, and certain types of white blood cells, including neutrophils, eosinophils, and basophils.
- Lymphoid cells develop into lymphocytes and natural killer (NK) cells, both of which play important roles in the immune system.
In leukemia, the DNA of a single cell in the bone marrow undergoes a change (mutation). DNA is the body’s genetic “instruction code,” telling cells when to grow, how to develop, and when to die. When this code is altered, leukemia cells continue multiplying uncontrollably. As these cells divide, they pass the same genetic mutation to all of their descendants.
Scientists do not yet know exactly what causes these mutations to occur. Research has, however, identified several recurrent genetic alterations shared by patients with different types of leukemia, helping improve diagnosis, risk stratification, and treatment selection.
Why Leukemia Is Different From Most Cancers
When people hear the word cancer, they often think of a mass (tumor) that grows gradually within a specific organ. Leukemia doesn’t generally form a tumor that shows up in imaging tests, such as X-rays or CT scans.
As leukemia cells accumulate within the bone marrow, they crowd out healthy blood-forming cells, leading to a decline in normal blood production. This explains why patients frequently develop several seemingly unrelated symptoms at the same time:
- Low red blood cell counts (anemia) can cause fatigue, shortness of breath, dizziness, and reduced exercise tolerance.
- Low platelet counts (thrombocytopenia) increase the likelihood of bruising, nosebleeds, bleeding gums, or tiny pinpoint red spots on the skin known as petechiae.
- Low numbers of functional white blood cells, or white blood cells that are present but unable to fight infection effectively, leave patients vulnerable to infections. Fever may become the first sign that medical attention is urgently needed.
Over time, leukemia cells may enter the bloodstream and circulate throughout the body, accumulating in organs such as the lymph nodes, spleen, liver, CNS and other tissues, depending on the type of leukemia.
Acute leukemia typically arises from an early arrest in the differentiation pathway, producing completely non-functional cancerous cells (blasts) that cause severe, fast-progressing symptoms. Some patients describe feeling well only a week before requiring hospitalization.
Chronic leukemia, on the other hand, often involves more mature, partially functional cells, resulting in milder, slower-developing symptoms.
Who Is at Higher Risk of Developing Leukemia?
Although leukemia can develop in anyone, several factors are associated with an increased risk:
- Previous cancer treatment. Prior treatment with chemotherapy or radiation therapy may increase the risk of developing certain types of leukemia, particularly acute myeloid leukemia (AML).
- Smoking. Cigarette smoking and prolonged exposure to secondhand smoke are associated with an increased risk of AML.
- Exposure to industrial chemicals. Long-term exposure to certain chemicals, particularly benzene, used in the manufacture of plastics, rubber, dyes, detergents, pesticides, and some industrial products, is a well-established risk factor for leukemia. Formaldehyde, another known carcinogen, has also been linked to an increased leukemia risk in certain occupational settings.
- Inherited genetic disorders. Some inherited conditions, including Down syndrome, neurofibromatosis, Klinefelter syndrome, and Shwachman-Diamond syndrome, are associated with a higher likelihood of developing leukemia.
- Family history. Certain types of leukemia may occur more frequently within families. In most cases, however, having a close relative with leukemia does not mean that another family member will develop the disease.
Nearly 500,000 people are diagnosed with leukemia worldwide each year, making it one of the most common malignancies. There are many types of leukemia. Some are more common in children, while others occur predominantly in adults.
When the Symptoms Do Not Seem Serious
One of the most challenging aspects of leukemia diagnosis is that the earliest symptoms are rarely specific. Persistent fatigue remains the most common complaint. Many patients attribute it to work, poor sleep, parenting responsibilities, or recovery from a recent viral illness. Others notice they become unusually short of breath while climbing stairs or exercising, despite having no previous health problems.
A bruise after minor trauma may not attract attention, but multiple unexplained bruises, prolonged bleeding after brushing teeth, or frequent nosebleeds deserve medical evaluation. Some experience repeated infections that seem unusually difficult to recover from. Others develop persistent fever without an obvious source, night sweats, bone pain, or an unintentional loss of weight.
Importantly, none of these symptoms confirms leukemia. Viral infections, autoimmune diseases, nutritional deficiencies, medication effects, and many other conditions can produce similar findings. This is one reason leukemia is often not suspected until laboratory testing reveals abnormalities.
Studies suggest that many patients with acute leukemia experience symptoms for several weeks before diagnosis, although the duration varies widely depending on the leukemia subtype, the biology of the disease, and individual health factors. Some present after repeated visits to primary care physicians, while others first seek medical attention in an emergency department because symptoms worsen rapidly.
Why Acute Leukemia Is a Medical Emergency
The urgency surrounding suspected acute leukemia is not driven simply by the diagnosis itself but by the complications that can develop before treatment even begins.
Very high white blood cell counts may impair blood flow through small vessels, a condition called leukostasis, which can affect the lungs or brain. Some patients develop severe bleeding due to low platelet counts or abnormalities in blood clotting.
Acute promyelocytic leukemia (APL), a distinct subtype of AML, deserves particular attention because it carries a high risk of life-threatening bleeding if treatment is delayed. For this reason, hematologists often begin targeted therapy as soon as APL is suspected, even before every laboratory result has returned.
The goal is not simply to diagnose leukemia but to prevent complications while identifying the precise subtype that will guide treatment.
The Blood Test That Changes the Conversation
After taking a medical history and performing a physical examination, the next step is usually a complete blood count (CBC). For many patients, the first indication that something serious may be happening comes from this simple blood test.
The CBC is one of the most commonly ordered laboratory tests in medicine, yet it provides an extraordinary amount of information. In suspected leukemia, the CBC often provides the first clue that the bone marrow is no longer functioning normally.
A Common Misconception
Many people believe leukemia always causes extremely high white blood cell counts. The name itself comes from the Greek words leukos (“white”) and haima (“blood”), reflecting the early observation of unusually high white blood cell counts in some patients. In reality, this is not always the case.
Some patients have markedly elevated white blood cell counts at diagnosis, while others present with normal, or even, low white blood cell numbers. This happens because leukemia disrupts normal blood cell production in the bone marrow, and the abnormal cells do not always circulate in large numbers in the bloodstream.
What often raises concern is not a single laboratory value but a pattern of abnormalities involving red blood cells, platelets, and white blood cells together. This is why physicians evaluate the complete blood count (CBC) as a whole rather than focusing on one number.
Peripheral Blood Smear Examination
Modern automated analyzers are highly sensitive and frequently generate alerts when abnormal cells are detected. These alerts do not establish a leukemia diagnosis, but they signal the need for closer examination.
The next critical step is often a peripheral blood smear. Rather than relying solely on automated measurements, a hematologist or laboratory specialist examines blood cells under a microscope. This allows them to assess whether immature blast cells are present, evaluate the appearance of normal blood cells, and identify patterns that may suggest specific leukemia subtypes or alternative blood disorders.
For patients, these tests may seem routine. For hematologists, they often represent the first pieces of a much larger diagnostic puzzle. A single blood sample can determine whether immediate hospital admission is necessary, whether additional emergency testing should be performed, and whether treatment planning must begin that same day.
At this point, leukemia is still only suspected. Confirming the diagnosis and determining exactly which type of leukemia is present, requires more specialized investigations, beginning with the bone marrow biopsy.
Looking Beyond the Blood: Why a Bone Marrow Biopsy Is Essential
After the initial blood tests raise concern for leukemia, most patients are told they need a bone marrow biopsy. For many, this is one of the most intimidating moments of the diagnostic journey. It is often the first unfamiliar procedure, and it usually comes at a time when patients are still trying to process the possibility of having cancer.
Despite its reputation, a bone marrow biopsy is generally a short procedure performed under local anesthesia. Patients remain awake, although some centers also offer mild sedation depending on the clinical situation and local practice. The sample is usually obtained from the back of the pelvic bone (the posterior iliac crest), where the bone marrow can be accessed safely without affecting the spine or the ability to walk.
The procedure consists of two parts. The first is bone marrow aspiration, during which liquid marrow is withdrawn through a needle. This sample contains individual blood-forming cells that can be examined under the microscope and used for specialized laboratory testing. The second is the core biopsy, which removes a small cylinder of bone and marrow tissue.
This preserves the architecture of the bone marrow and allows pathologists to evaluate how leukemia cells have replaced normal blood-forming tissue. In some cases, particularly when only a bone marrow aspirate is needed, the sample may instead be taken from the sternum (breastbone).
The pathologist determines how much of the marrow has been replaced by leukemia cells, identifies the type of leukemia, evaluates whether normal blood production remains, and obtains material for advanced laboratory studies that directly influence treatment decisions.
Clinician’s Perspective
A bone marrow biopsy is not ordered because physicians want “one more test.” It serves as the foundation of the entire treatment plan.
Also, modern hematology combines morphology with immunology, cytogenetics, and molecular genetics to create an increasingly precise diagnosis. The World Health Organization and the International Consensus Classification now define several leukemia subtypes based partly on their genetic characteristics.
For patients, this often means additional blood samples shortly after the bone marrow biopsy. Repeating blood draws may seem excessive, but each tube serves a different purpose.
Flow Cytometry: Looking for Unique Cell Markers
One of the first specialized tests performed is flow cytometry, often available within hours. Every blood cell carries proteins on its surface that act like identification markers. Flow cytometry analyzes thousands of cells individually and determines which markers they express. This information helps physicians answer several critical questions:
- Is this leukemia or another blood disorder?
- Is it AML or ALL?
- If it is ALL, does it arise from B lymphocytes or T lymphocytes?
- Are there features that will later help detect measurable residual disease (MRD)?
Flow cytometry has become indispensable because treatment strategies differ substantially between leukemia subtypes.
Cytogenetics: Looking at the Chromosomes
The next layer of information comes from cytogenetic testing, which examines the chromosomes inside leukemia cells.
Chromosomes contain our genetic material. Sometimes entire chromosomes are missing, duplicated, or rearranged. Some chromosomal abnormalities predict a favorable response to treatment, while others indicate a higher likelihood of relapse after remission. Certain abnormalities also identify patients who may benefit from stem cell transplantation during first remission rather than chemotherapy alone.
Although conventional chromosome analysis usually requires several days because leukemia cells must grow in the laboratory before they can be examined, the information it provides remains one of the cornerstones of leukemia risk assessment.
Molecular Testing: Reading the Genetic Instructions
Perhaps the greatest transformation in leukemia diagnosis over the past two decades has been the widespread use of molecular testing. Instead of examining entire chromosomes, molecular techniques identify changes within individual genes.
In AML, physicians commonly test for mutations involving genes such as FLT3, NPM1, CEBPA, IDH1, IDH2, TP53, RUNX1, and several others. In ALL, molecular testing may identify abnormalities such as ETV6::RUNX1, TCF3::PBX1, and KMT2A rearrangements, as well as the BCR::ABL1 fusion gene (Philadelphia chromosome).
These results are no longer simply descriptive. Many directly determine therapy.
Patients with FLT3-mutated AML often receive a FLT3 inhibitor alongside chemotherapy. Those with IDH mutations may become candidates for targeted inhibitors during relapse or, in selected settings, frontline treatment. Patients with Philadelphia chromosome-positive ALL routinely receive tyrosine kinase inhibitors in combination with chemotherapy or immunotherapy.
The First 24-72 Hours: What Patients Experience and What the Medical Team Is Doing
For patients and family members, the first days after diagnosis often feel chaotic. Blood is drawn repeatedly. Intravenous medications begin before chemotherapy starts. Meanwhile, the hematology team is following a carefully organized plan.
Stabilizing the Patient
Many patients require red blood cell transfusions to improve oxygen delivery and reduce symptoms of anemia. Others receive platelet transfusions to lower the risk of bleeding.
Intravenous fluids are frequently started early to support kidney function and reduce complications associated with rapid breakdown of leukemia cells after treatment begins.
Patients with fever receive broad-spectrum antibiotics promptly because infections can progress rapidly in individuals with impaired immune function. Importantly, physicians often begin antibiotics before identifying the exact organism responsible. Waiting for culture results would unnecessarily delay treatment in a potentially life-threatening situation.
Preventing Tumor Lysis Syndrome
One of the first medications many patients receive is allopurinol or, in higher-risk situations, rasburicase. These drugs are used to prevent tumor lysis syndrome (TLS), a potentially serious complication that occurs when large numbers of leukemia cells break down and release their contents into the bloodstream.
As cells break apart, potassium, phosphate, nucleic acids, and other intracellular substances enter the circulation. If these changes become severe, they can impair kidney function, disturb heart rhythm, and create additional medical emergencies.
More Blood Tests Than Expected
Many patients are surprised by how often blood is drawn during the first hospitalization. Blood counts, electrolytes, kidney function, liver function, clotting parameters, and markers of tumor lysis can change rapidly, particularly once treatment begins.
In acute leukemia, laboratory values provide a real-time picture of how the disease and the patient’s body are responding. Thus frequent laboratory monitoring allows physicians to adjust transfusions, medications, fluid therapy, supportive care and stay ahead of complications rather than reacting after they occur.
The First Weeks After Diagnosis: What Patients and Families Can Expect
Receiving a leukemia diagnosis affects much more than physical health. Research in psycho-oncology has shown that patients diagnosed with acute leukemia experience particularly high levels of psychological distress during the first weeks after diagnosis, largely because hospitalization is often immediate and treatment begins before they have had time to adjust to the diagnosis. Several practical strategies can make this period more manageable:
Bring Someone to Important Conversations
Even highly educated patients rarely remember everything discussed during the first consultations. A trusted family member or friend can help take notes, ask questions, and remember information that may otherwise be forgotten.
Ask Questions Repeatedly
Patients sometimes hesitate to ask the same question twice. Physicians expect this. Understanding leukemia is a gradual process, not a single conversation. As treatment progresses, information that seemed overwhelming during the first day often becomes much easier to understand.
Focus on Reliable Sources
A leukemia diagnosis usually leads patients to search the internet immediately. Unfortunately, online information varies enormously in quality. Resources produced by organizations such as the Leukemia & Lymphoma Society (LLS), the American Society of Hematology (ASH), the National Comprehensive Cancer Network (NCCN), and major academic cancer centers provide information that is regularly updated and reviewed by experts.
Accept That the Treatment Plan May Change
Some patients expect physicians to outline the entire treatment journey on the first day. Leukemia treatment is rarely planned that far in advance. As new laboratory results become available, molecular testing is completed, and the patient’s response to therapy becomes clearer, recommendations often evolve. This does not indicate uncertainty, it reflects personalized, evidence-based decision making.
How Is Leukemia Treated?
Treatment often involves a combination of the following approaches:
Chemotherapy: Chemotherapy is the most common form of leukemia treatment. It uses drugs to kill leukemia cells or prevent them from multiplying. Treatment may be given as pills, intravenous (IV) infusions, or injections under the skin. Most patients receive a combination of chemotherapy drugs.
Immunotherapy (biologic therapy): This treatment uses drugs that help the immune system recognize and attack leukemia cells. Some immunotherapies also stimulate the production or activity of immune cells that fight cancer.
Targeted therapy: Targeted therapies are designed to attack specific molecules, such as proteins or genetic abnormalities, that drive the growth and survival of leukemia cells. These drugs may stop leukemia cells from multiplying, block important signaling pathways, or kill the cells directly. Because they target specific abnormalities, they are generally less likely to harm normal cells.
Hematopoietic stem cell transplantation (HSCT): Also called a stem cell transplant or bone marrow transplant, replaces blood-forming cells destroyed by high-dose chemotherapy, with or without radiation therapy, with healthy hematopoietic stem cells. These cells may be collected from the patient’s own blood or bone marrow before treatment or obtained from a compatible donor. The transplanted stem cells then establish healthy bone marrow and restore normal production of blood cells.
Chimeric antigen receptor (CAR) T-cell therapy: CAR T-cell therapy is an advanced form of immunotherapy in which a patient’s own T cells are collected, genetically engineered to recognize leukemia cells, and then infused back into the bloodstream to attack the cancer.
Clinical trial enrollment: Clinical trials evaluate new treatments and treatment combinations that may improve outcomes for patients with leukemia. Participation should be discussed with the treating healthcare team after carefully considering the potential benefits and risks.
The Phases and Duration of Leukemia Treatment
Depending on the treatment plan, leukemia therapy may be delivered continuously over a prolonged period or in distinct phases. Each phase has a specific goal.
Induction therapy: The goal is to destroy as many leukemia cells as possible in the blood and bone marrow and achieve complete remission. During remission, blood cell counts recover, leukemia cells are no longer detectable in the blood, and the signs and symptoms of the disease resolve. Induction therapy typically lasts four to six weeks.
Consolidation therapy(also called intensification): The goal is to eliminate any remaining leukemia cells that cannot be detected with routine tests, reducing the risk of relapse. Consolidation therapy is usually given in several cycles over four to six months.
Maintenance therapy: The goal is to eliminate any leukemia cells that may have survived the earlier phases of treatment and help prevent relapse. When indicated, maintenance therapy commonly continues for about two years.
Modern leukemia care combines disease-directed therapy with intensive supportive medicine: infection prevention, transfusion support, nutritional assessment, pain management, management of nausea, psychological support, fertility counseling when appropriate, and careful evaluation of heart, liver, and kidney function.
These measures are not secondary considerations. Numerous studies have shown that improvements in supportive care have contributed substantially to the improved survival seen in acute leukemia over the past several decades.
What Determines Prognosis After a Leukemia Diagnosis?
One of the first questions nearly every patient asks is, “What are my chances?” It is also one of the most difficult questions for a hematologist to answer during the first few days after diagnosis. Outcomes depend on a variety of factors:
The type of leukemia, considering that even within the broad categories, there are numerous biological subtypes. Acute promyelocytic leukemia, once considered one of the most lethal forms of leukemia because of severe bleeding complications, has become one of the most curable adult leukemias following the introduction of differentiation therapy with all-trans retinoic acid (ATRA) and arsenic trioxide. Long-term survival now exceeds 90% in many contemporary studies when patients receive prompt diagnosis and appropriate treatment.
Modern prognosis assessment depends heavily on genetics. In AML, mutation types help classify disease into favorable-, intermediate-, or adverse-risk categories according to the European LeukemiaNet (ELN) recommendations. In ALL, chromosomal abnormalities and molecular alterations, including the Philadelphia chromosome, influence both treatment decisions and prognosis.
Age and Overall Health: Age remains an important consideration, but it is no longer viewed in isolation. A physically fit 70-year-old may tolerate intensive therapy better than a younger patient with significant heart disease, kidney dysfunction, or other chronic illnesses. For this reason, hematologists increasingly evaluate physiological fitness rather than chronological age alone when designing treatment plans.
Early Response to Treatment: Perhaps the strongest predictor of long-term outcome is how leukemia responds to initial therapy.
Many patients hear the term complete remission after induction chemotherapy. Complete remission means that leukemia cells can no longer be detected using conventional microscopic examination, blood counts have recovered, and normal blood production has resumed.
Today, physicians often look beyond complete remission by measuring measurable residual disease. Patients who achieve MRD-negative remission generally have a lower risk of relapse than those with detectable residual leukemia, making MRD one of the most important prognostic biomarkers.
How Chronic Leukemias Follow a Different Diagnostic Path
While this article focuses primarily on acute leukemia, it is important to recognize that not all leukemias present as medical emergencies.
Many patients with Chronic Lymphocytic Leukemia (CLL) feel completely well when the disease is discovered. Diagnosis frequently begins with an incidental finding of elevated lymphocyte counts during routine blood work performed for unrelated reasons. Unlike acute leukemia, immediate treatment is often unnecessary. Many patients remain under active surveillance, commonly called “watch and wait”, for months or even years before treatment becomes necessary.
Chronic Myeloid Leukemia (CML) is also frequently identified through routine blood testing. Once diagnosed, molecular testing confirms the presence of the BCR::ABL1 fusion gene, which drives the disease.The introduction of tyrosine kinase inhibitors has been one of the greatest advances in oncology, allowing many patients with CML to achieve long-term disease control with oral medication. The contrast highlights an important point:
Living With a Leukemia Diagnosis: Remission and Long-Term Outlook
Any cancer diagnosis is scary, but a leukemia diagnosis may feel especially so. It can be difficult to imagine what the treatment experience will be like without a tumor that can be removed.Yet, it is important to remember that leukemia is not one disease with one outcome. Their symptoms, diagnostic pathways, urgency, treatments, and long-term outcomes differ substantially.
Remission may last anywhere from a few weeks to many years, and in some cases, the leukemia may never return. If it does, the healthcare team may recommend additional treatments to achieve remission again. Whether leukemia can be considered cured is a question best answered by the healthcare team. They will work closely with each patient to monitor their health, assess for signs of recurrence, and develop an individualized approach.
Written by Susanna Mikayelyan, MD